Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453194 | 0.96 | IDO1 (0.60) | TP53MAPK1L3MBTL1IDO1MAPT | |
| SCHEMBL9797612 | 0.88 | LMNA (0.64) | TP53MAPK1L3MBTL1IDO1MAPT | |
| SCHEMBL4573884 | 0.88 | CA12 (0.51) | TP53MAPK1L3MBTL1IDO1SMN1; SMN2 | |
| SCHEMBL16593002 | 0.88 | AAK1 (0.61) | TP53HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL16593036 | 0.85 | CA12 (0.51) | IDO1SMN1; SMN2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL21601440 | 0.85 | AAK1 (0.49) | L3MBTL1IDO1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL21601453 | 0.85 | KDM4E (0.54) | TP53IDO1HPGDSMN1; SMN2RAB9A | |
| SCHEMBL16939134 | 0.84 | HPGD (0.54) | TP53MAPK1L3MBTL1IDO1MAPT | |
| SCHEMBL12409191 | 0.84 | KDM4E (0.62) | MAPK1IDO1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL21601218 | 0.84 | IDO1 (0.53) | MAPK1IDO1HPGDSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104846-B1 | MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER | UNIV SOUTHERN CALIFORNIA (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3104846-B1 | MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER | UNIV SOUTHERN CALIFORNIA (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10561663-B2 | MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180360843-A1 | MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER | UNIV SOUTHERN CALIFORNIA (US) | 2018-12-20 | — | — | US | disclosed |
| EP-2736506-B1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | UNIV SOUTHERN CALIFORNIA (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180185303-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185303-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185303-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-07-05 | — | — | US | disclosed |
| US-9771625-B2 | Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771625-B2 | Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160339034-A9 | MAO Inhibitors and Their Conjugates as Therapeutics For The Treatment of Brain Cancer | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160339034-A9 | MAO Inhibitors and Their Conjugates as Therapeutics For The Treatment of Brain Cancer | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2015120206-A9 | MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015120206-A1 | MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20150209361-A1 | MAO Inhibitors and Their Conjugates as Therapeutics For The Treatment of Brain Cancer | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150209361-A1 | MAO Inhibitors and Their Conjugates as Therapeutics For The Treatment of Brain Cancer | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2736506-A2 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | University Of Southern California (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20130039854-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039854-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2013016580-A2 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360843-A1 | MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER | MAOA, MAOB, COMT | TP53 1706/4885MAPK1 2652/4885L3MBTL1 3733/4885 |
| US-20180185303-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | MAOA, COMT, MAOB | TP53 2599/4885MAPK1 4288/4885L3MBTL1 1531/4885 |
| US-20130039854-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | MAOA, COMT, MAOB | TP53 2599/4885MAPK1 4288/4885L3MBTL1 1531/4885 |
| US-10561663-B2 | MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer | MAOA, MAOB, COMT | TP53 1706/4885MAPK1 2652/4885L3MBTL1 3733/4885 |
| US-20150209361-A1 | MAO Inhibitors and Their Conjugates as Therapeutics For The Treatment of Brain Cancer | MAOA, MAOB, COMT | TP53 1706/4885MAPK1 2652/4885L3MBTL1 3733/4885 |
| US-20160339034-A9 | MAO Inhibitors and Their Conjugates as Therapeutics For The Treatment of Brain Cancer | MAOA, MAOB, COMT | TP53 1706/4885MAPK1 2652/4885L3MBTL1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.